Stock Titan Trading tools for traders and investors.

-

08:25:35 AM

Last JAGX Stock Market News

JAGX - Jaguar Health Inc

10/13/20 8:30 AM

NASDAQ : JAGX

Jaguar Health Provides Updates Regarding Company Capitalization Strategy

Jaguar Has Closed on the First $6 Million Tranche of the Previously Announced Non-Dilutive Royalty Financing Transaction - Which Now Has the Potential to Total $17 Million Jaguar and its Subsidiary, Napo Pharmaceuticals, Enter into Fourth Amendment to the Accounts Receivable Purchase Agreement with

RHEA-AI

neutral

10/07/20 8:30 AM

NASDAQ : JAGX

Jaguar Health Subsidiary Napo Pharmaceuticals Initiates Pivotal Phase 3 Clinical Trial of Crofelemer (Mytesi) for Prophylaxis of Diarrhea in Adult Cancer Patients Receiving Targeted Cancer Therapy

A Significant Proportion of Patients Receiving Targeted Cancer Therapy Experience Diarrhea Initial Tranche of Non-dilutive Financing Transaction Increased from $5 Million to $6 Million by Mutual Consent with Lender, Providing Additional Q4 2020 Funding for Pivotal Phase 3 Clinical Trial and a Total

RHEA-AI

neutral

10/06/20 8:30 AM

NASDAQ : JAGX

Jaguar Health Meets Financial Condition for Sale of Royalty Rights for Mytesi (Crofelemer) Indications

Financial Condition for Initial $5 Million Tranche of Potential $16 Million Non-dilutive Financing Transaction Achieved through the Establishment of an At-the-Market Program Yesterday for Potential Future Financing Needs, if Any, with Ladenburg Thalmann Aggregate Royalty Proceeds of Potential $16

RHEA-AI

very positive

10/02/20 8:30 AM

NASDAQ : JAGX

Jaguar Health's Mental Health Entheogen Therapeutics Initiative Targets Plant-based Candidate Compound for Possible Schizophrenia and Psychoses Indications

Jaguar Health, Inc. (NASDAQ:JAGX) announced today that the company's recently launched mental health

RHEA-AI

positive

10/01/20 8:30 AM

NASDAQ : JAGX

Jaguar Health Signs Agreement for Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) Revenue Stream for $5 Million, with Possible Future Tranches in 2021, Totaling $16 Million

RHEA-AI

very positive

09/28/20 8:30 AM

NASDAQ : JAGX

Jaguar Health Subsidiary Napo Pharmaceuticals Sponsoring 2020 National Trans Visibility March

Jaguar Health, Inc. (NASDAQ:JAGX) announced today that the company's wholly owned subsidiary, Napo Pharmaceuticals, Inc. (Napo), is a proud sponsor of this year's

RHEA-AI

neutral

09/24/20 8:30 AM

NASDAQ : JAGX

Jaguar Health to Host Exclusive Virtual Educational Event "Diarrhea Dialogues: Why Bowel Control is Critical to Supportive Care in Cancer"

Leading Oncologists, Supportive Care Experts, and Patient Advocates Discuss Importance of Supportive Care for Cancer Patients and Address Debilitating Diarrhea Resulting from Cancer Therapy Virtual Event and Q&A 3:00 PM to 4:30 PM EDT on October 20 Registration Open Now for Financial and Business

RHEA-AI

neutral

09/16/20 8:30 AM

NASDAQ : JAGX

Jaguar Health Establishes World-Class Scientific Strategy Team to Support Newly Launched Mental Health Entheogen Therapeutics Initiative

Jaguar Health, Inc. (NASDAQ:JAGX) announced today the formation of

RHEA-AI

very positive

09/11/20 8:30 AM

NASDAQ : JAGX

Jaguar Health to Present at Virtual H.C. Wainwright 22nd Annual Global Investment Conference September 16

Jaguar Health, Inc. (NASDAQ:JAGX) announced today announced that Lisa Conte, Jaguar's founder, president and CEO, will present at the virtual 2020 H.C. Wainwright 22 nd Annual Global Investment Conference on Wednesday, September 16, 2020, at

RHEA-AI

neutral

09/10/20 8:30 AM

NASDAQ : JAGX

Jaguar Health and its Subsidiary, Napo Pharmaceuticals, Enter into Third Amendment to the Accounts Receivable Purchase Agreement with Oasis Capital, LLC, Dated May 12, 2020

Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar and its wholly owned subsidiary, Napo Pharmaceuticals,

RHEA-AI

very positive

Prev 1 2 3 4 5 Next